Currently, both peptides are approved for MACE reduction based on the following data: The effectiveness of semaglutide for reducing MACE risk was studied in the SUSTAIN-6 trial, which included a total of 3297 diabetics, the majority of which had cardiovascular risks
According to the results, adults taking Mounjaro were more likely to lose 5%, 10% and 15% of their body weight compared to those who were taking Ozempic, which is the brand name for semaglutide
While not a weight loss treatment on their own, the increased energy often helps clients maintain more active lifestyles, which can support weight management goals
A B12 injection is a clinical procedure: site rotation, clean technique and correct dosing matter, which is why a trained clinician is the safest place to have one
Gesuete, V., Ragni, L., and Picchio, F
However, its promise demands rigorous, mechanistically grounded inquiry